The role of gut hormones replacement in improving blood flow to the brain after stroke that affects swallowing.

Phase 1

• Conditions: We plan to give a synthetic form of GLP-1 (Liraglutide) that is already available and licensed for use in patients with diabetes in the UK, to patients who have had an acute stroke, in order to determine whether increased levels protect the brain during its recovery, resulting in better recovery.; MedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2011-003572-36-GB
• Lead Sponsor: Royal Devon & Exeter NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-06
• Last Update Posted: 10 December 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients over the age of 18 years, presenting within 6 hours of an acute stroke who are able to consent or have next of kins who can provide assent and are planned to be placed nil by mouth for at least 12 hours.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

Inability to provide informed consent or inability to contact a relative or carer who can provide assent. Stroke as a result of an intra-cerebral bleed. Pregnancy and breast feeding. Liver impairment, Type I diabetes, Patients who are on insulin, Sulphonylurea therapy or other GLP-1 treatment, Hypersensitivity to Liraglutide Other contraindication for the use of Liraglutide (as per SmPC).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified